KAERI used its RFT-30 cyclotron, a device that is used for the development of medical radioisotopes and basic science research using proton beams, to produce the Cu-67. It will be supplied to local medical institutions starting in the second half of 2020.

"PET scans are widely used for diagnosing cancer, but antibodies or peptides that contain Cu-67 can carry out both scanning and therapy. Cu-67 also has a relatively short half-life of 2.6 days, which means it is less dangerous, so it has been widely regarded as a next-generation radioisotope for cancer treatment," a KAERI official said.

To read more please visit:

https://www.koreatimes.co.kr/www/tech/2020/03/133_285533.html